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Abstract
Molecular epidemiology studies face a missing data problem, as biospecimen or imaging data are 
often collected on only a proportion of subjects eligible for study. We investigated all molecular 
epidemiology studies published as Research Articles, Short Communications, or Null Results in 
Brief in Cancer Epidemiology, Biomarkers & Prevention from January 1, 2009, to March 31, 
2010, to characterize the extent that missing data were present and to elucidate how the issue was 
addressed. Of 278 molecular epidemiology studies assessed, most (95%) had missing data on a 
key variable (66%) and/or used availability of data (often, but not always the biomarker data) as 
inclusion criterion for study entry (45%). Despite this, only 10% compared subjects included in 
the analysis with those excluded from the analysis and 88% with missing data conducted a 
complete-case analysis, a method known to yield biased and inefficient estimates when the data 
are not missing completely at random. Our findings provide evidence that missing data methods 
are underutilized in molecular epidemiology studies, which may deleteriously affect the 
interpretation of results. We provide practical guidelines for the analysis and interpretation of 
molecular epidemiology studies with missing data.
Introduction
With the advent of new technology to measure biomarkers, studies in molecular 
epidemiology have become increasingly more common. As a result, many epidemiology 
studies now collect biospecimens such as blood, buccal, urine, or tissue samples to evaluate 
biomarkers that may provide insight into the underlying pathogenesis of disease or that may 
be predictive of prognosis. Imaging studies, such as mammography, positron emission 
tomography, and functional MRI, are also used to measure relevant biomarkers of disease.
Generally, biospecimens and image-based data are available only for a subset of the subjects 
in the study, posing a missing data problem. Occasionally, even when samples are available, 
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measurements may be subject to censoring (i.e., partially missing) due to the detection limit 
of an assay. Missing data methods, however, are not typically being employed. In a 1995 
study, Greenland and Finkle (1) discussed the underutilization of missing data methods in 
epidemiology studies due to their inaccessibility and complexity. Although missing data 
methods such as imputation are more readily available at present, a recent study by 
Klebanoff and Cole in 2008 (2) found that less than 2% of articles published in 
epidemiology journals make use of imputation-based methods. Instead, a common approach 
is to conduct a complete-case (CC) analysis (1, 2): exclusion of subjects missing data on at 
least one variable considered in the analysis. Our study characterizes the prevalence of 
missing data specifically in molecular epidemiology studies and provides an in-depth 
description of how the issue is addressed.
There are a variety of reasons biomarker data may be missing in molecular epidemiology 
studies, some of which may be related to the actual values of the biomarkers themselves 
and/or other variables; these underlying reasons matter. Specifically, CC approaches are 
statistically valid, that is, they provide unbiased point estimates and CIs that achieve nominal 
coverage (3), only when data are missing completely at random (MCAR), that is, when 
missingness is unrelated to observed or unobserved data yielding a study sample that is 
representative of the larger cohort (3, 4). For example, consider a batch of randomly selected 
samples for which measurements are not observed because of an instrumentation 
malfunction, as occurred in the study by Clendenen and colleagues (5); it is reasonable to 
assume that these data are MCAR. In this case, a CC analysis should not yield biased 
estimates, although the estimates may suffer from efficiency loss. If missingness is related 
only to observed variables, the data are considered missing at random (MAR). An example 
of this may be given by Mavaddat and colleagues (6), who examined the role of common 
single-nucleotide polymorphisms (SNP) in subtypes of breast cancer. These authors found 
that those eligible for study without samples for genotyping were more likely to have 
advanced stage breast cancer (III/IV). In this case, the data may be MAR if, conditional on 
stage, the probability of missing SNP information is not related to the unobserved SNP 
values. If, however, the reason for missing data is related to the unobserved values, the data 
are not missing at random (NMAR). For example, suppose tumor size is measured less 
frequently on smaller tumors, as in the study described by Gilcrease and colleagues (7), 
these data would be considered NMAR. CC analyses conducted on data that are not MCAR 
(i.e., MAR or NMAR) can lead to biased and inefficient estimates.
Often one can infer whether missingness is related to observed variables, as Mavaddat and 
colleagues (6) conducted in their analysis comparing those included in the analysis with 
those excluded from the analysis, which may suggest MCAR is not a reasonable assumption 
for the variable in question. Distinguishing between NMAR and MAR patterns, however, is 
not feasible without making unjustifiable assumptions, as it is impossible to examine the 
nature of missingness for data that do not exist. Thus, one may rely on assumptions based on 
biological, clinical, and epidemiologic understandings.
There are theoretically sound methods for analyzing data that are either MAR or NMAR. 
For MAR data, likelihood-based methods and standard multiple imputation (MI) are 
examples of statistically valid approaches. Furthermore, MI is particularly simple to 
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implement and readily available (4). Analogous methods (likelihood-based and MI-based) 
exist for NMAR data, although they are not as easily accessible and are more complex to 
implement (4, 8–14). The increase in complexity is due to the need to model the missing 
data distribution (or missing data mechanism), whereas assuming the data are MAR 
generally allows one to ignore this aspect.
The goals of this article are to characterize the extent that missing data are present in 
molecular epidemiology studies, to elucidate how the issue is being addressed, and to 
discuss MI as a possible, practical solution.
Materials and Methods
Missing data in molecular epidemiology studies
Cancer Epidemiology, Biomarkers & Prevention (CEBP) is a high-ranked journal that 
frequently reports on molecular epidemiology studies. We examined all molecular 
epidemiology studies published as Research Articles, Short Communications, or Null 
Results in Brief in this journal from January 1, 2009, through March 31, 2010. A molecular 
epidemiology study was defined as an observational study either using both epidemiologic 
data (such as demographic or clinical data) and molecular data obtained from a biospecimen 
such as tissue, saliva, or serum or using image-based data such as MRI or mammographic 
imaging data to address a research question. Studies that conducted meta-analyses were 
excluded for 2 reasons: (i) the state of missing data was difficult to assess because they 
involve multiple studies each of which has its own inclusion and exclusion criteria; and (ii) 
these studies typically summarize results from individual studies. Pooled studies, on the 
other hand, were included, as these were viewed as single studies that applied consistent 
inclusion/exclusion criteria across subjects to combine cohorts to address a question.
Although any analytic approach including CC may be considered a method for handling 
missing data, we considered missing data methods to be tools applied for the purpose of 
including subjects in the analysis in the presence of both missing outcome and covariates. 
This includes likelihood-based methods, single and multiple imputations, and the use of 
missing data indicators. For longitudinal outcomes (such as time-to-event data or repeated-
measures data), Cox proportional hazards models or mixed-effects models are examples of 
methods that accommodate missing outcome data; subjects can be included as long as they 
are measured for at least one time point, and validity relies on an MAR assumption for the 
outcome. If no additional attempt was made, however, to include subjects with missing 
covariates, the study was classified as not having employed a missing data method.
We characterized the most common types of study designs encountered in molecular 
epidemiology studies and calculated the percentage of studies that (i) had missing data, (ii) 
used availability of data as a criterion for inclusion into their study, (iii) used missing data 
methods when relevant, (iv) described differences between those included in and excluded 
from analysis, and (v) implemented a CC analysis.
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Molecular epidemiology studies included in our assessment
Of all 534 studies in the Research Articles, Short Communications, or Null Results in Brief 
sections of CEBP, there were 278 studies that satisfied our inclusion criteria. Of these, 
38.1% were cross-sectional cohort studies, 28.1% were standard case–control studies (i.e., in 
which cases and controls were recruited by the authors for the purpose of the study), 17.3% 
were nested case–control studies (in which cases and/or controls were obtained from another 
observational or experimental study designed for a different purpose), 14% were 
longitudinal cohort studies, and 2.5% (7 total) were pooled studies (i.e., in which 4 were 
pooled case–control studies and 3 were pooled cohort studies (see Fig. 1 for a graphical 
display).
Characterization of missing data in molecular epidemiology studies
Figure 2 graphically describes the prevalence of missingness in the studies included for 
assessment and how the issue was addressed. Table 1 similarly tabulates relevant 
frequencies. Of the 278 studies included in our assessment, 265 (95%) either had missing 
data or used availability of data as an inclusion criterion for study entry. More specifically, 
66% (184) had missing data on at least one biomarker or key variable of interest. The 
percentage missing (on the biomarker or key variable) ranged from 0.1% to 98%, with a 
median percentage missing of 14% and a mean of 22% (for 10 of the studies with missing 
data, we could not determine the percentage of subjects with missing data). Of the 94 
articles that did not have missing data, 81 articles (85%) used availability of data as an 
inclusion criterion for entry into the study. The remaining 13 articles neither had missing 
data nor used availability of data as inclusion criterion. Eleven of these articles were studies 
that appropriately defined the population of interest through use of a biospecimen, such as 
men with histologically confirmed prostate cancer. The remaining 2 studies did not claim to 
have any missing data, nor did they claim to use availability of data as an inclusion criterion, 
which was surprising (15, 16). For example, the study by Wang and colleagues (15), who 
investigated hepatocellular carcinoma, followed a cohort of 5,929 participants over an 8-year 
period. Although survival analytic techniques were applied to account for differences in 
lengths of follow-up (i.e., missing data on the outcome, time to development of 
hepatocellular carcinoma), notably absent was any mention of missing baseline data. All 
5,929 patients were successfully classified at baseline for hepatitis B and C infection, as well 
as diabetes status, using blood samples; for the latter, both fasting blood glucose and 
nonfasting glucose levels were measured, indicating 2 blood draws. In addition, data on 
demographics and health behaviors were captured for the entire cohort. It is certainly 
possible that because hepatocellular carcinoma is relatively common in this population from 
southern Taiwan, the participants were highly motivated to comply.
Of those studies with missing data, 85% acknowledged that they had missing data, although 
surprisingly, only 14% described differences in some aspect between those with and without 
available data. Nine of the 184 studies with missing data involved measures that were 
partially missing or censored because of assays with limits of detection. Only 23 studies 
with missing data used some type of missing data method (all 9 studies using assays with 
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detection limits are included among these). All of these involved some form of single 
imputation (17 studies including all 9 with assay detection limits) and/or use of missing data 
indicators (7 studies). For example, although Platek and colleagues (17) excluded subjects 
missing data on the biomarker, diet, and alcohol consumption, they imputed the median 
value for the remaining continuous variables and created a missing category for categorical 
variables. All remaining studies with missing data (88%) used a CC analysis.
Discussion
Missing data in molecular epidemiology studies
A large percentage of the studies we examined (66%) had missing data. Furthermore, a large 
percentage used availability of data (45%; often, but not always, the biospecimen or 
imaging-based data) as an inclusion criterion for study entry (and a small percentage fell 
into both categories). This was not surprising, given the design of these studies. For 
example, nested case–control studies draw their subjects from other existing cohorts, such as 
the Women’s Health Initiative (WHI), the Nurses’ Health Study, the Physician’s Health 
Study, and the Surveillance Epidemiology and End Results (SEER) registry. Epidemiologic 
data (such as demographics and health behavior data) may be available on a large proportion 
in these cohorts, whereas data from biospecimens or images will typically only be available 
on a smaller proportion. If one defines the study population strictly by relevant patient 
characteristics such as age, gender, race, and particular disease features, one will inevitably 
face a missing data issue for research questions that involve data from a biospecimen or 
image. Some investigators, however, alternatively used availability of data as part of the 
definition of the study population in the hope of avoiding a missing data problem. 
Unfortunately, as systematic differences between those with and without the biomarker may 
exist, the potential for bias remains; excluding these individuals prior to study entry has the 
same impact as excluding them at the time of analysis.
Only 85% of the studies missing data made some mention of this in the article (e.g., by 
mentioning that not all study subjects contributed to the estimated point estimates, or that 
not all subjects who provided blood samples had corresponding genotype values due to an 
assay error.) Thus, it is likely that many investigators were unaware that they were dealing 
with a missing data issue that could contribute to bias. This may partly explain the absence 
of comparisons between the participants and nonparticipants (only 10% of the studies 
described differences on some aspect) among those eligible or among those who would have 
been eligible and were having a biospecimen (or image) not part of the inclusion criteria. 
Another possible explanation for excluding this level of detail may be the word count 
restrictions of the journal.
Missing data methods used
Only a small percentage of the studies with missing data employed a missing data method 
(13%). Those that did used single imputation and/or missing data indicators. Advantages of 
the single imputation approach are as follows: standard complete data methods can be used; 
the approach has computational ease (there is only one set of imputations generated and no 
need for specialized software); and one can incorporate the investigator’s knowledge into the 
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imputation. The disadvantage, however, is that a singly imputed value reflects neither 
sampling variability about the actual value under a particular model for missingness nor 
variability corresponding to multiple models considered. This can result in an overstatement 
of precision (14). The use of missing data indicators to retain a group of subjects is a popular 
approach that can be applied when the data are either categorical or continuous. Although it 
seems simple and intuitive, it is known to yield biased estimates even under an MCAR 
condition (14).
MI: A potential practical solution
Missing data methods that yield statistically valid results need to become more customary. 
Both MI and likelihood-based methods are statistically valid and rely on an assumption of 
missingness that is more flexible than that of CC and closer to what is expected from a 
typical molecular epidemiology study. MI is a simulation-based method for handling 
missing data, and similar to likelihood-based methods, it can simultaneously accommodate 
data that are missing on more than one variable. Unlike many likelihood-based methods, 
however, MI methods are readily available in mainstream software packages such as SAS, 
SPSS, STATA, and R. An additional advantage of MI over likelihood-based approaches is 
the additional ease in which auxiliary variables can be incorporated into MI, thereby 
enhancing the estimation. This is discussed in detail by Collins and colleagues (18).
There are 3 main steps involved in conducting an MI-based analysis. The first step consists 
of imputing plausible values for missing data from a specified distribution, the full 
complexity of which will be addressed in the following subsections. To incorporate the 
uncertainty of the imputed values, this is done m times to create m complete data sets, where 
m typically varies between 3 and 10. The data are analyzed separately for each of the m data 
sets in step 2, with the estimates appropriately combined to yield one summary result in step 
3. The theoretical underpinnings of the method are described in Little and Rubin (4).
Limitations of MI—MI is theoretically sound under the MAR condition. In practice, 
however, its performance will not be robust if it is poorly applied or if the missing data 
mechanism is incorrectly specified. In the following text, we discuss 4 drawbacks to using 
MI: (i) the increase in burden on the user to assess whether the unverifiable assumption 
about the data mechanism (MAR) is appropriate; (ii) the varying performance of different 
imputation methods; (iii) the varying answers for each application of MI to the same data 
set; and (iv) the need for specialized software.
Limitation 1: Relying on unverifiable assumptions about the missing data mechanism 
for validity: An advantage of MI over CC is that it accommodates a more flexible 
assumption about missingness, whereas a disadvantage is that it increases the burden on the 
user by requiring careful specification of the imputation model in order for this assumption 
to hold. Although users rarely investigate whether the MCAR assumption holds, taking a CC 
approach does not avoid the need to assess assumptions about missingness, but the task may 
be easier: a simple check of whether those with and without data on the key variable differ 
can provide great insight.
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Assuming the data are MAR, on the other hand, is equivalent to assuming that the 
information needed to impute the missing values can be found in the observed data. This 
requires both careful consideration of auxiliary information (variables that may enhance 
estimation, given the state of missingness) and one to rely on strong a priori knowledge of 
biological and clinical mechanisms. Incorporating auxiliary variables into missing data 
methods was studied extensively by Collins and colleagues (18). A useful auxiliary variable 
may be one that correlates with the variable for which the data are missing or one that 
correlates with missingness, or both. An example of the former may be tumor site, if it 
correlates with tumor size, where tumor size is missing. An example of an auxiliary variable 
that correlates with missingness may be advanced stage if those with more serious disease 
are more likely to provide biospecimens for genotyping.
Standard MI is not recommended when the data are suspected to be NMAR. For example, 
while Taylor and colleagues promote using MI to reduce nonresponse bias in epidemiology 
studies, they recommend doing so only when the MAR assumption is likely to hold (19). In 
molecular epidemiology studies, however, one may suspect that the data are NMAR based 
on a priori knowledge. Even so, the presence of strong auxiliary information may allow one 
to proceed with methods that assume MAR. It is difficult, however, to quantify the strength 
of the auxiliary variable(s) needed to assume MAR. This raises an important question, which 
is, were MAR not reasonable (e.g., if the data were truly NMAR and there were an absence 
of good auxiliary variables), would one be better off with a CC analysis than with a standard 
MI approach that assumes MAR? Desai and colleagues (20) compared the performances of 
CC and standard MI methods for this situation in a simulation study conducted in the 
context of missing exposure variables where interactions were being assessed. When 
extreme values of the covariate were more likely to be missing, MI yielded estimates that 
were more biased than those of CC. In the other situations examined (where the log odds of 
missing was a linear function of the variable with missing data), the bias from the 2 
approaches was similar (although in all situations, the estimates achieved greater efficiency 
with MI than with CC). A follow-up question is: would a CC analysis be superior to a 
special application of an MI-based analysis appropriate for NMAR data? More specifically, 
if one were to suspect that the data are NMAR, one could use special models such as pattern 
mixture models or selection models that involve explicitly modeling the missing data 
mechanism in an MI-based analysis (14). Results, however, are known to be sensitive to 
misspecification of the model, for which the assumptions cannot be verified. It is, therefore, 
possible for such an approach to perform worse than CC.
Although making unverifiable assumptions about the missing data mechanism is a serious 
drawback to using MI, a strength is its ability to incorporate the uncertainty of these 
assumptions into the results, where the assumptions may involve the missing data 
mechanism (NMAR versus MAR), different sets of auxiliary variables to include under the 
MAR condition, and various models under the NMAR condition. These results can also 
serve as a sensitivity analysis to get a sense of the robustness of the results.
Limitation 2: Varying performance of imputation methods: A second limitation is that 
different algorithms for producing MI vary in performance and thus the imputation method 
employed by the software can also have a bearing on the results. In general, the strategies for 
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imputing fall into 1 of 2 classes: the joint modeling approach, which typically relies on a 
multivariate normality assumption and for which sound statistical properties have been 
established, or the fully conditional specification approach, which is more flexible in 
accommodating variables of different types but has less tractable statistical properties (13). 
SAS, for example, uses MI based on the joint modeling approach, whereas STATA uses the 
fully conditional approach. In his comparative study, van Buuren found the joint modeling 
approach to be more biased than the fully conditional specification approach. He 
recommends that the fully conditional specification approach be applied when no convenient 
and realistic joint distribution can be specified. For more details on the comparison of these 
approaches, see van Buuren (13).
Limitation 3: Varying answers for each application of MI: A third drawback is that 
because it is simulation based, MI produces a slightly different answer each time it is applied 
to the same data set. This may happen as the number of imputations varies, or even if the 
same number of imputations is used but the data sets are newly created. This undesirable 
property is not shared by CC- or likelihood-based methods. The implications of this 
limitation, however, are negligible in practice.
Limitation 4: Need for specialized software: Finally, the need for specialized software to 
apply MI can create a dependence on statistical support where it may not have existed when 
using the usual CC methods. Although this does add complexity over a CC analysis, MI 
methods are much more accessible than many of the likelihood-based methods (see Allison 
for a guide on accessing software for implementing likelihood-based methods; ref. 14) and 
are relatively easily implemented. To illustrate its ease of use, we provide example code 
implemented via the ICE and MICOMBINE procedures, developed by Patrick Royston for 
use in STATA (21–23) in Appendix A. Other software implementing MI can be found in the 
comprehensive review of Horton and Kleinman (24).
Censored measurements due to assays with limits of detection: a special case of missing 
data in molecular epidemiology studies
Much of our discussion has focused on data that are completely missing as opposed to 
partially missing, as when an assay does not detect levels below or above a certain point. For 
example, in HIV studies, the number of copies of HIV RNA per milliliter of plasma is an 
important marker of disease progression. The standard branched DNA assay for measuring 
HIV molecules, however, cannot detect levels below 50 HIV copies/mL (25). In this case, 
we may not know the exact number of HIV molecules in the sample, but we do know that 
the sample contains no more than 50 copies/mL.
Sixty-two percent of the studies we assessed made use of some sort of assay to measure a 
biomarker of interest, and 9 reported having issues with limit detection. In practice, assays 
have lower limits of detection and the resulting data are therefore left-censored. Methods 
specific for handling left-censored data should be considered in these situations and include 
both likelihood- and MI-based approaches. As the data are more likely to be censored for 
extreme values (outside of the range of the assay), the data are NMAR. Common approaches 
are to treat the data as missing, or to singly impute (as all 9 studies did in our assessment) as 
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0, the detection limit, or half the detection limit. These approaches are known to result in 
biased estimates, where the bias increases as the proportion of censored observations 
increases. Considerable work has been devoted to this area of study (e.g., refs. 26–28). For 
methods specific to data censored because of limits of detection, we refer the reader to the 
work of Hughes (27), in which performances between imputation- and likelihood-based 
methods are compared, a likelihood-based method is recommended, and software can be 
obtained by E-mailing the author.
Practical guidelines for handling missing data
In the following, we present a series of steps to incorporate into an analysis when faced with 
missing data.
Step 1: Describe targeted study population—A description of those eligible for 
study should be provided and unless relevant for defining subjects (e.g., those with 
histologically confirmed prostate cancer) should not include criteria relating to the 
availability of outcome or covariate data.
Step 2: Clearly describe derivation of analytic data set—Molecular epidemiology 
studies are often obtained from existing data sources, and, in these cases, the original 
sources should either be described or referenced. Critical to valid interpretation of the 
results, however, is the derivation of the analytic sample, that is, who was included and 
excluded. Ideally, this should match the description of the study population. In their study 
relating exposure of high-dose estrogen during adolescence to mammographic density in 
adulthood, Jordan and colleagues (29) provide an excellent example of a clear description of 
which patients were eligible to study and of which patients were ultimately analyzed by 
making use of a flowchart figure.
Step 3: Describe population characteristics of subjects in analytic data set 
including missing and/or censored data—Often description of the study population 
is provided. In cases wherein point estimates for describing relations are derived on the 
complete cases only (a subset of the study population), however, description of the analytic 
data set is crucial for interpretation, particularly if missingness is systematic.
Step 4: Describe differences between those with and without data on key 
variables with respect to population characteristics—In addition to aiding in 
interpretation of results, this also serves as an assessment of the MCAR assumption. 
Drawing from the earlier example, Jordan and colleagues observed that nonparticipants 
eligible for study (or those missing data on mammographic density) differed from 
participants in age at interview but not with respect to height, body mass index (BMI), and 
history of having had a breast biopsy (29).
Step 5: Investigate possible assumptions for missing data mechanism
• Assume that the data are MCAR if there is no evidence of its violation (as 
determined in step 4) and there is no known mechanism for generating NMAR 
data.
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• Assume that the data are MAR if the MCAR condition was violated, there is no 
known mechanism for generating NMAR data, and candidate auxiliary variables 
exist.
• Assume that the data are NMAR if a priori knowledge indicates that the missing 
values are related to the unobserved values. Common situations that give rise to 
NMAR data are when subjects are unable or unwilling to provide measurements 
because of the unobserved values (e.g., they are too sick to be evaluated and 
disease severity is measured), or the tool for measuring the variable cannot assess 
values outside its range (e.g., assays with limits of detection).
The latter 2 points need further qualification. For the first, if the MAR condition seems 
theoretically plausible, one must consider the presence of auxiliary variables that will make 
this assumption likely to hold in practice. For example, the analysis conducted by Jordan and 
colleagues (29) indicates that the data are not MCAR. Whether the data are MAR or whether 
it is possible that those with particular breast densities are more or less prone to participate is 
unknowable. It does not seem likely, however, that breast density would be related to 
participation and therefore it is reasonable to assume that the data are MAR. Auxiliary data 
are still required, however, for this condition to hold. Data that correlate with breast density 
(e.g., BMI) and/or missingness (age at interview) play an important role in satisfying this 
condition and need to be incorporated. For the second, even if the NMAR condition is 
suspected, auxiliary variables may still allow the MAR condition to hold. For example, if 
disease severity were being measured over several time points, and a priori knowledge 
indicates that those with missing values are more likely to be those who are too sick to come 
into the clinic for assessment, then the NMAR condition should be suspected. Assessments 
at other visits, however, may be correlated with missing scores at a given time point and 
could be used as auxiliary variables, making the MAR condition more plausible after 
conditioning on these variables. On the other hand, the MAR condition may not be 
appropriate in cases for which the study design requires only one disease severity 
assessment per patient.
Step 6: Conduct a CC analysis—If one can assume that the data are MCAR and a 
small proportion of the data are missing, this can serve as the sole and primary analysis. 
Otherwise, additional analyses should be conducted (see step 7).
Step 7: Choose an additional analytic approach if necessary—A standard MI 
analysis is a reasonable choice under MAR conditions (or MCAR in the presence of a large 
proportion of missing data for possible gains in efficiency). If NMAR is likely (even after 
considering auxiliary variables), special applications of MI-based methods can still be used; 
however, the missing data mechanism must be modeled and several NMAR models should 
be posed. These models are more complicated in both implementation and software 
accessibility and are discussed in greater detail by others (4, 14). If at least one of the 
missing variables is one that is subject to censoring due to limits of detection, a likelihood-
based approach as described by Lyles and colleagues (26) and Hughes (27) is recommended.
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Step 8: Implement the additional missing data methods—Auxiliary variables 
should be considered for optimal performance. More specifically, one needs to make sure 
that the variables specified in the imputation model include (i) all the variables in the 
scientific model including the dependent variable, (ii) any variables related to missingness of 
the variable(s), and (iii) any variable(s) correlated with those for which data are missing so 
that MAR can hold. When faced with the choice of which auxiliary variables to include in 
imputing the variable (s) of interest, however, Collins and colleagues (18) showed through 
simulation studies that being more inclusive even when doubtful of the usefulness of some 
auxiliary variables resulted in increased efficiency and reduced bias. In the study by Jordan 
and colleagues (29), this would involve including all variables in the scientific model 
(selected using forward-stepwise regression), the outcome (the mammographic measure), 
age at interview because it correlated with missingness, and any variables correlated with the 
mammographic measure (e.g., BMI). Although height and history of breast biopsy were not 
related to missingness, they should be included if they relate to the mammographic measure 
or they were included in the scientific model. The specific form of the model will be dictated 
by the choice in software, as discussed in the limitations section. As suggested by van 
Buuren, this choice depends on whether the variables considered are of mixed type (i.e., 
some combination of continuous, categorical, ordinal, or binary variables) or whether a 
realistic joint distribution can be specified (13). If the latter is considered, software that uses 
the joint modeling approach (e.g., SAS) is recommended. Otherwise, software that employs 
the fully conditional specification approach is recommended (e.g., STATA or R).
Step 9: Conduct a sensitivity analysis—If missing data methods are employed, one 
should do a sensitivity analysis by fitting various models. If the proportion of data missing is 
not small and the data are MCAR, both CC and MI analyses can be done, wherein various 
MAR conditions (i.e., different sets of auxiliary variables) are considered. If NMAR is 
suspected, CC, MI approaches using different sets of auxiliary variables under MAR, and 
special application of MI approaches under several NMAR models should be conducted. 
The array of results can be presented to describe the robustness of the findings across the 
various assumptions. In addition, the uncertainty of these assumptions can be taken into 
account when presenting summarized findings. For other tips and tricks on implementing MI 
including how many imputations to be done, see Allison’s excellent book on missing data, 
which provides more detailed practical guidelines and examples for applying MI in 
nontechnical language (14).
Step 10: Interpret results—If a consensus is easily reached across analyses, this makes 
interpretation (and presentation) straightforward. In situations where findings differ by 
assumptions, the authors will have to weigh in on what is most plausible, given their 
understandings of the biology, and present the array of results so the reader can understand 
how the assumptions affected the overall interpretation.
Conclusions
In summary, we have shown that molecular epidemiology studies face a particularly 
challenging missing data problem in that the majority of these studies will be missing data 
on the key variable of interest, the biomarker. Although it seems sensible to study only those 
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with the measured biomarker, we argue the importance of including those who would be 
eligible for study despite the missing biomarker. At the very least, we urge comparison of 
features between those with and without missing data. We strongly encourage the 
incorporation of missing data methods into the analysis when it is warranted. More 
specifically, if comparisons indicate that the data are not MCAR, and MAR seems 
reasonable, we highly recommend the use of standard MI. Even in cases where the data are 
MCAR, one can benefit from MI in efficiency. If it is likely that the data are NMAR and one 
can assume the presence of strong auxiliary information, standard MI may still be a 
reasonable estimation-enhancing tool. Otherwise, MI that models the missing data 
mechanism is a possibility. A useful feature of MI is that it allows for incorporation of 
uncertainty of these factors into the results.
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Appendix A: STATA Code for Implementing MI
/*Read in data set where interest is in estimating effects
   of 2 risk factors on case-control status*/
/* X1 and X2 are risk factors of interest and Z is a potential
    auxiliary variable */
      insheet using “~/scen1.csv”,
      clear
/*Use ICE to fit imputation model creating 10 imputed
   data sets*/
/* All variables in scientific model are included in imputation model in 
addition to auxiliary variable */
        ice case x1 x2 z, saving(simimpute.dta) m(10) replace
/*Read in data set containing all 10 imputed data sets*/
       use simimpute.dta, clear
/*Use MICOMBINE to fit the desired scientific model (a
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   logistic regression model that includes the risk factors
   of interest) and combine results across 10 data sets*/
      micombine logit case x1 x2
Desai et al. Page 14














Articles considered for inclusion in assessment.
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Presence of and techniques used to address missing data for studies assessed.
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Table 1
Descriptive statistics relevant to missingness among studies assessed
Characteristic Number of articles %
Included in assessment among all CEBP Research Articles, Short Communications, and Null Results in Brief from 
January 1, 2009 to March 31, 2010 (N = 534)
278 52
Had missing data among articles included (N = 278) 184 66
Used data availability as inclusion criterion among articles included (N = 278) 126 45
Either had missing data or used availability of data as part of inclusion criteria among assessed (N = 278) 265 95
Acknowledged presence of missing data among those with missing data (N = 184) 157 85
Used CC analysis among those with missing data (N = 184) 161 88
Used missing data methods among those with missing data (N = 184) 23 13
Used single imputation to address limits of detection among those who used a method (N = 23) 9 39
Described differences between those included in and excluded from analysis among those with missing data (N = 
184)
26 14
Described differences between those included in and excluded from analysis among those with either missing data 
or that used data availability as inclusion criterion (N = 265)
27 10
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